Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1573-7322
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin ; day:29 ; month:4 ; year:2022 ; pages:1-13
Heart failure reviews ; (29.4.2022), 1-13

Creator
Aimo, Alberto
Senni, Michele
Barison, Andrea
Panichella, Giorgia
Passino, Claudio
Bayes-Genis, Antoni
Emdin, Michele
Contributor
SpringerLink (Online service)

DOI
10.1007/s10741-022-10228-8
URN
urn:nbn:de:101:1-2022071010313130497377
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:20 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Aimo, Alberto
  • Senni, Michele
  • Barison, Andrea
  • Panichella, Giorgia
  • Passino, Claudio
  • Bayes-Genis, Antoni
  • Emdin, Michele
  • SpringerLink (Online service)

Other Objects (12)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Comorbidities in heart failure with preserved ejection fraction

Comorbidities in heart failure with preserved ejection fraction

Biomarkers in heart failure with preserved ejection fraction

Biomarkers in heart failure with preserved ejection fraction

Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis

Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1–STING axis

Animal models of heart failure with preserved ejection fraction

Animal models of heart failure with preserved ejection fraction

Heart Failure with Preserved Ejection Fraction—a Concise Review

Heart Failure with Preserved Ejection Fraction—a Concise Review

Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials

Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials

133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction

133 Obesity is associated with decreased myocardial contraction fraction despite preserved ejection fraction

Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure

Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure

Gender-related differences in heart failure with preserved ejection fraction

Gender-related differences in heart failure with preserved ejection fraction

Role of renin–angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction

Role of renin–angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction

Related objects